112 PATENT ABSTRACTS

The present invention disclosed novel recom- binant DNA cloning vectors including pMND1000 and vectors derived therefrom for use in Streptomyces and related organisms. These novel cloning vectors contain genetic mar- kers that provide an.tibiotic resistance or colorimetric selectivity to the host cells. The in- vention further comprises transformants of the aforementioned vectors.

4701407

D I A G N O S I S O F A L Z H E I M E R D I S E A S E

Stanley H Appel assigned to Baylor College of Medicine

The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Par- kinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hor- mone. Diagnosis is accomplished by assaying hormones specific for a particular neuronal net- work or system: the motor neurotr0phic hor- mones from muscle in the motor neural system are used to diagnose and treat ALS, dopamine neurotrophic hormones from striatum in the nigrostriatal neural system are used to diagnose and treat parkinsonism, and cholinergic neurotrophic hormones released from the cortex and hippocampus which are specific for cholinergic neurons of the nucleus basalis and septal nucleus are used to diagnose and treat Alz- heimer's disease. With tissue culture, the pre- sence or absence of specific neurotrophic hormones can be assessed in ALS, par- kinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic hormones specific to the particular neuronal net- work or system can be injected in ALS and Alz- heimer disease and in parkinsonism.

4713325

H Y B R I D O M A S P R O D U C I N G M O N O C L O N A L A N T I B O D I E S

S P E C I F I C F O R F E L V P27

Hans Lutz, Ruedlinger, Switzerland assigned to The Regents of the University of California

Compositions and method are described for the detection of feline leukemia virus. Hybridomas are prepared producing monoclonal antibodies specific for at least one determinant site for the protein p27 of feline leukemia virus (FeLV). The

antibodies are used in an enzyme immunoassay for determination of feline leukemia virus.

8704714

P O L Y P E P T I D E W I T H I N T E R L E U K I N - 2 A C T I V I T Y

Tsutomu NISHIDA, Masaaki TAKANO, Naoki NISHINO, Yasukazu OHMOTO, Fumitsugu ISHIGAMI, Yoshikatsu HIRAI, 240-18, Ooshiro, Otsu-cho, Naruto-shi, Tokushima 772, Japan assigned to OTSUKA PHARMACEUTICAL CO LTD;

A polypeptide with an interleukin-2 activity, in which at least one amino acid present in the amino acid sequence of the 2nd to 1 l th positions or the 128th to 133rd positions from the N ter- minal (Ala) of human interleukin-2 and its equi- valent peptide is lost or substituted. A process for its preparation is also disclosed.

8704719

M E T H O D F O R T H E E X T R A C T I O N O F A V I T A M I N - K - D E P E N D E N T

C A R B O X Y L A S E C O M P L E X A N D T H E U S E T H E R E O F

Cornelis VERMEER, Berry Aloysius Maria SOUTE, Parkweg 2B, N L-6212 XN Maastricht, Netherlands assigned to RIJKSUNIVER- SITEIT LIMBURG

Method for the extraction and insolubilisation of a vitamin-K-dependent carboxylase complex from biological material, for instance a bovine liver homogenate, which can be used for the con- version of, for example, precursors of the blood coagulation factors II, VII, X and especially IX prepared via recombinant DNA-technology, the insolubilised carboxylase complex, as well as the prepared biologically active blood coagulation factors to be used in pharmaceutical composi- tions.

87047~

HYBRID PLASMINOGEN A C T I V A T O R - L I K E P O L Y P E P T I D E

Michito TAGAWA, Masakatsu WADA, Masayuki YAMANDA, Midori YOKOYAMA, Naganori NUMAO, 3-16,